The European Commission approved Merck’s Erbitux on July 14, 2026. This regulatory green light covers Erbitux in combination with encorafenib and FOLFOX for adult patients with first-line BRAF V600E-mutant metastatic colorectal cancer.
Data from the Phase 3 BREAKWATER trial supported the approval. The trial demonstrated significant improvements in survival rates for patients using the combination therapy.
JPMorgan, BMO Capital Markets, and Guggenheim recently raised their price targets for Merck following the announcement. This financial optimism also follows a separate FDA expansion for Keytruda in bladder cancer treatment.